Teva Pharmaceuticals shares are trading lower following a report suggesting that the FTC opened an investigation into the company's asthma and COPD inhaler patents. Separately, a court ordered that Vanda's HETLIOZ patent lawsuit against the company and Apotex may proceed.
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceuticals shares are down due to an FTC investigation into its asthma and COPD inhaler patents. Additionally, a court has allowed Vanda's HETLIOZ patent lawsuit against Teva and Apotex to proceed.
July 01, 2024 | 2:28 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Teva Pharmaceuticals shares are trading lower following news of an FTC investigation into its asthma and COPD inhaler patents. Additionally, a court has allowed Vanda's HETLIOZ patent lawsuit against Teva and Apotex to proceed.
The FTC investigation into Teva's inhaler patents could lead to regulatory actions or fines, negatively impacting the company's financials. The court's decision to allow Vanda's patent lawsuit to proceed adds further legal risk and potential financial liabilities.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100